March 21, 2013

DPP-4 inhibitors showing Promise Preventing Diabetes in HIV



The chances of a person with HIV becoming a diabetic is twice as great compared to the general population. Doctors are testing the diabetes drug class known as DPP-IV inhibitors to see if it can stave-off the full-blown effects of diabetes.

An article in the  Journal of Clinical Endocrinology & Metabolism shows how drugs available to people with diabetes may help people with HIV avoid developing diabetes.

DPP-IV inhibitors increase insulin production by insulin-producing cells and inhibit glucose production by the liver, when glucose levels are high. Current brand names of DPP-IV inhibitors are Januvia and Onglyza.

Since people with HIV have a compromised immune system, and DPP-IV inhibitors act on specific sites in all cells of the body this pilot study evaluated the safety and efficacy in this method. So far it has proven successful. Ongoing studies will evaluate further cardio-metabolic benefits.

The saying an ounce of prevention is worth a pound of cure holds true if DPP-IV inhibitors can help deflect the development for anyone, including people affected with HIV.

Visit Your Diabetes Health for more resources about health.